VNRX

VolitionRx enacted a one-for-twenty reverse stock split on April 29, 2026. NYSE American accepted the company's compliance plan after a notice of non-compliance. Volition announced a breakthrough in finger-prick detection of nucleosomes and submitted a manuscript for its Nu.Q® Vet Cancer Test in cats. The company launched its rNuQ™ Webshop and announced its full fiscal year 2025 financial results, reporting increased revenue but also significant losses and a "going concern" audit opinion. A Mayo Clinic study demonstrated elevated Nu.Q® concentrations in trauma patients, and Volition secured EUR 2.0 million in non-dilutive funding. Analysts have a consensus rating of "Moderate Buy" with a high price target, although some have decreased their targets. The stock price has decreased by 56.0% since the start of 2026.